Found 3 articles
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021.
5/7/2021Biopharmaceutical company CRISPR Therapeutics has entered into a strategic research, development and commercialization partnership with cancer-focused Nkarta.
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities